canertinib dihydrochloride has been researched along with sb 202190 in 1 studies
| Studies (canertinib dihydrochloride) | Trials (canertinib dihydrochloride) | Recent Studies (post-2010) (canertinib dihydrochloride) | Studies (sb 202190) | Trials (sb 202190) | Recent Studies (post-2010) (sb 202190) |
|---|---|---|---|---|---|
| 31 | 13 | 6 | 651 | 0 | 202 |
| Protein | Taxonomy | canertinib dihydrochloride (IC50) | sb 202190 (IC50) |
|---|---|---|---|
| Mitogen-activated protein kinase 13 | Homo sapiens (human) | 0.08 | |
| Bromodomain-containing protein 4 | Homo sapiens (human) | 2.95 | |
| Tyrosinase | Mus musculus (house mouse) | 0.03 | |
| Amine oxidase [flavin-containing] B | Rattus norvegicus (Norway rat) | 0.08 | |
| Casein kinase I isoform delta | Homo sapiens (human) | 0.188 | |
| Mitogen-activated protein kinase 12 | Homo sapiens (human) | 0.08 | |
| Mitogen-activated protein kinase 11 | Homo sapiens (human) | 0.1038 | |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | 0.0625 | |
| Tau-tubulin kinase 2 | Homo sapiens (human) | 9.34 | |
| large T antigen | Betapolyomavirus macacae | 4.87 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Russu, WA; Shallal, HM | 1 |
1 other study(ies) available for canertinib dihydrochloride and sb 202190
| Article | Year |
|---|---|
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship | 2011 |